Grand Opening of the 2025 Sustainable Global Leaders Conference: Kevin Kelly and the Turing Award Winner Share AI Frontiers, Business Leaders Discuss Sustainable Development
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- Approved by the State Council, the 2025 Sustainable Global Leaders Conference opened on October 16 in Huangpu District, Shanghai. Centered around the theme "Joining Hands to Address Challenges: Global Action,...
Discover the charms of Mie Prefecture's Ise-Shima region on the Kintetsu Railway. Savor local cuisine, timeless traditions, and the beauty of nature with all five senses.
From bustling cities to the great outdoors OSAKA, Japan, Oct. 20, 2025 /PRNewswire/ -- The Expo 2025 Osaka, Kansai, which wrapped up to resounding acclaim, drew a total of 25,578,986 visitors by October 13, having already surpassed the benchmark of...
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3...
Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session
SUZHOU, China, Oct. 18, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company and...
Yunji Technology Debuts on HKEX, Partners with Luxshare Precision to Accelerate Global Expansion
HONG KONG, Oct. 18, 2025 /PRNewswire/ -- Beijing Yunji Technology Co., Ltd. (the "Company"; Stock code: 2670) today announced that shares of the Company have started to be traded on the Main Board of The Stock Exchange of Hong Kong Limited under the...
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other
AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities Promising efficacies were observed in patients...
Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
CHENGDU, China, Oct. 17, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab botidotin...
Meiji Sweets Ambassador FRUITS ZIPPER Promotes Meiji Gummy "Poifull" in Taipei on First Day of Group's Asia Tour
- Poifull Handed Out to Fans to Make Their Day "A Little Happier" - TOKYO, Oct. 17, 2025 /PRNewswire/ -- Meiji Co., Ltd., headquartered in Tokyo, collaborates with the seven-member idol group FRUITS ZIPPER, which is Meiji Sweets Ambassador, on the...
ANA and Miyazaki Prefecture Collaborate on "Miyazaki Destination Campaign" for Chinese Tourists Visiting Japan
TOKYO, Oct. 17, 2025 /PRNewswire/ -- ANA Akindo Co., Ltd., All Nippon Airways Co., Ltd. (ANA) and Miyazaki Prefecture will jointly implement the "Miyazaki Destination Campaign" for Chinese tourists visiting Japan. In conjunction with ANA's campaign...
Yiwu Global Digital Trade Center Opens, Setting Worldwide Digital Commerce Benchmark
YIWU, China, Oct. 17, 2025 /PRNewswire/ -- Yiwu Global Digital Trade Center, flagship project of the city's sixth-generation market, officially opened on Oct. 14. The launch completes the market's latest upgrade and signals Yiwu's shift from...